

Tadashi Ikegami

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6805465/publications.pdf>

Version: 2024-02-01

34
papers

1,205
citations

471509

17
h-index

434195

31
g-index

34
all docs

34
docs citations

34
times ranked

1878
citing authors

#	ARTICLE	IF	CITATIONS
1	Highly sensitive quantification of key regulatory oxysterols in biological samples by LC-ESI-MS/MS. <i>Journal of Lipid Research</i> , 2009, 50, 350-357.	4.2	165
2	Highly sensitive analysis of sterol profiles in human serum by LC-ESI-MS/MS. <i>Journal of Lipid Research</i> , 2008, 49, 2063-2073.	4.2	140
3	Regulation of bile acid metabolism in mouse models with hydrophobic bile acid composition. <i>Journal of Lipid Research</i> , 2020, 61, 54-69.	4.2	115
4	Cholesterol 25-hydroxylation activity of CYP3A. <i>Journal of Lipid Research</i> , 2011, 52, 1509-1516.	4.2	99
5	Ursodeoxycholic acid: Mechanism of action and novel clinical applications. <i>Hepatology Research</i> , 2008, 38, 123-131.	3.4	93
6	Highly sensitive quantification of 7 α -hydroxy-4-cholesten-3-one in human serum by LC-ESI-MS/MS. <i>Journal of Lipid Research</i> , 2007, 48, 458-464.	4.2	65
7	Increased serum liver X receptor ligand oxysterols in patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2012, 47, 1257-1266.	5.1	54
8	Liver Fibrosis: Possible Involvement of EMT. <i>Cells Tissues Organs</i> , 2007, 185, 213-221.	2.3	53
9	Involvement of integrin-linked kinase in carbon tetrachloride-induced hepatic fibrosis in rats. <i>Hepatology</i> , 2006, 44, 612-622.	7.3	51
10	Highly sensitive and specific analysis of sterol profiles in biological samples by HPLC-ESI-MS/MS. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2010, 121, 556-564.	2.5	49
11	Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C. <i>Hepatology Research</i> , 2017, 47, 1429-1437.	3.4	41
12	Detection of Gut Dysbiosis due to Reduced Clostridium Subcluster XIVa Using the Fecal or Serum Bile Acid Profile. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1035-1044.	1.9	40
13	Increased serum oxysterol concentrations in patients with chronic hepatitis C virus infection. <i>Biochemical and Biophysical Research Communications</i> , 2014, 446, 736-740.	2.1	37
14	Reciprocal interactions between bile acids and gut microbiota in human liver diseases. <i>Hepatology Research</i> , 2018, 48, 15-27.	3.4	37
15	Real-world efficacy and safety of 12-week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection. <i>Hepatology Research</i> , 2021, 51, 51-61.	3.4	20
16	Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease. <i>Hepatology Research</i> , 2018, 48, 549-555.	3.4	19
17	Hepatitis C virus infection causes hypolipidemia regardless of hepatic damage or nutritional state: An epidemiological survey of a large Japanese cohort. <i>Hepatology Research</i> , 2011, 41, 530-541.	3.4	17
18	Effect of native vitamin D ₃ supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin. <i>Hepatology Research</i> , 2016, 46, 450-458.	3.4	15

#	ARTICLE	IF	CITATIONS
19	Efficacy of direct-acting antiviral treatment in patients with compensated liver cirrhosis: A multicenter study. <i>Hepatology Research</i> , 2019, 49, 125-135.	3.4	15
20	Evaluation of 8-week glecaprevir/pibrentasvir treatment in direct-acting antiviral-naïve noncirrhotic HCV genotype 1 and 2-infected patients in a real-world setting in Japan. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1266-1275.	2.0	13
21	Transforming growth factor- β signaling and liver cancer stem cell. <i>Hepatology Research</i> , 2009, 39, 847-849.	3.4	11
22	Influencing factors on serum 25-hydroxyvitamin D3 levels in Japanese chronic hepatitis C patients. <i>BMC Infectious Diseases</i> , 2015, 15, 344.	2.9	10
23	Efficacy and safety of ombitasvir/paritaprevir/ritonavir and ribavirin for chronic hepatitis patients infected with genotype 2a in Japan. <i>Hepatology Research</i> , 2019, 49, 369-376.	3.4	9
24	Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4939.	4.1	8
25	Circulating bile acid profiles in Japanese patients with NASH. <i>GastroHep</i> , 2019, 1, 302-310.	0.6	7
26	Western Diet Changes Gut Microbiota and Ameliorates Liver Injury in a Mouse Model with Human-Like Bile Acid Composition. <i>Hepatology Communications</i> , 2021, 5, 2052-2067.	4.3	7
27	Impact of determination of hepatitis B virus subgenotype and pre-core/core-promoter mutation for the prediction of acute exacerbation of asymptomatic carriers. <i>Hepatology Research</i> , 2009, 39, 341-345.	3.4	5
28	Differences in the Serum 4 β -hydroxycholesterol Levels of Patients with Chronic Hepatitis C Virus (HCV) Infection: A Possible Impact on the Efficacy and Safety of Interferon (IFN)-free Treatment. <i>Internal Medicine</i> , 2018, 57, 1219-1227.	0.7	3
29	Mac-2-binding protein glycan isomer predicts all malignancies after sustained virological response in chronic hepatitis C. <i>Hepatology Communications</i> , 2022, 6, 1855-1869.	4.3	3
30	Efficacy and safety of 12-week sofosbuvir/velpatasvir treatment of patients with decompensated liver cirrhosis caused by hepatitis C virus infection. <i>Acta Hepatologica Japonica</i> , 2020, 61, 276-278.	0.1	2
31	Efficacy and Safety of Glecaprevir/Pibrentasvir Combination Therapy in Genotype 1b Chronic Hepatitis C Patients with and without Cirrhosis Undergoing Hemodialysis. <i>Acta Hepatologica Japonica</i> , 2018, 59, 578-580.	0.1	1
32	Evaluation of the Risk of Clostridium difficile Infection Using a Serum Bile Acid Profile. <i>Metabolites</i> , 2022, 12, 331.	2.9	1
33	Alteration of intracellular taurine transporter expression in CCl ₄ -induced liver disease. <i>FASEB Journal</i> , 2007, 21, A667.	0.5	0
34	A case of the stenosis of the terminal ileum during taking NSAIDs. <i>Progress of Digestive Endoscopy</i> , 2010, 77, 108-109.	0.0	0